Document is current
Any future updates will be listed below
-
Authors
Bennison, Sarah A.
Blazejewski, Sara M.
Liu, Xiaonan https://orcid.org/0000-0002-3181-8310
Hacohen-Kleiman, Gal
Sragovich, Shlomo https://orcid.org/0000-0003-3847-6584
Zoidou, Sofia
Touloumi, Olga
Grigoriadis, Nikolaos
Gozes, Illana https://orcid.org/0000-0001-9796-2430
Toyo-oka, Kazuhito https://orcid.org/0000-0002-0173-0430
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS096098-01A1, F31NS113404-01A1)
U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (F31HD103405-01A1)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
- License Information
-
More Information
Article History
Received: 25 February 2021
Revised: 13 December 2022
Accepted: 22 December 2022
First Online: 11 January 2023
COMPETING INTERESTS
: NAP (CP201, davunetide) use is under patent protection (US patent nos. US7960334, US8618043, US10912819 and WO2017130190A1) (IG), PCT/IL2020/051010 (IG) and provisional patent applications have been submitted (IG inventor and contributing scientist SS). Davunetide is exclusively licensed to ATED Therapeutics LTD (IG, Co-Founder and Chief Scientific Officer).
